Patient J
A 17-year-old girl was transported by ambulance to the emergency room for treatment of acetaminophen intoxication (300 mg/kg acetaminophen). Fifteen ml of syrup of ipecac was administered and the patient transported to the hospital. The initial acetaminophen level (4 hours after ingestion) was 256 mcglml. The first three doses of n-acetylcysteine (NAC) were promptly followed by emesis. This included two doses of 5% NAC administered over one hour by slow nasogastric (NG) administration. Ondansetron (0.15 mglkg) was administered intravenously and repeated every eight hours for a total of three doses. Thirty minutes following the first dose of ondansetron, NAC (140 mglkg) was administered by NG tube over one hour, followed by 70 mglkg every four hours for a total of 17 doses. No further emesis occurred. Liver function tests and coagulation profile were monitored every day for five days and showed no evidence of liver dysfunction. The patient has subsequently done well.
Patient 2
A 13-year-old, 48 kg girl was admitted to the ICU following spinal fusion for idiopathic scoliosis. Analgesia was initiated with a patient controlled analgesia (PCA) device set to deliver morphine 2 mg every 10 minutes, as needed, without a basal infusion rate. The patient did well for the initial 24 hours with haemoglobin saturations of 94 to 96% on room air. On the second postoperative day, she developed nausea and vomiting. Initial treatment consisted of promethazine 12.5 mg intravenously, every 6 hours as needed. Fifteen mi~utes follo~ing a dose of promethazine, hypoxaemia (saturatlOns of 78 to 80% by pulse oximetry) and respiratory depression (respiratory rate of 6) were noted. ThiS Anaesthesia and IntenSll'e Care. Vol. 20. No. 4. NOI'ember. 1992 was immediately treated with supplemental oxygen and naloxone (0.1 mg) intravenously, which resulted in a prompt increase in her respiratory rate and oxygen saturation. Review of the PCA dosing revealed that she had received 3 doses over the past 2 hours, the most recent dose being administered 10 minutes prior to the promethazine dose. The promethazine was discontinued and further complaints of nausea and vomiting were treated with ondansetron (0.15 mg/kg every 6 hours as needed). The patient subsequently received three doses of ondansetron and the remainder of her postoperative course was uncomplicated.
Patient 3
A nine-year-old girl was admitted to the ICU following posterior fossa exploration with excision of a medulloblastoma. During the first six hours of her postoperative course, she developed persistent vomiting. Her neurologic examination was otherwise unremarkable. The vomiting was initially treated with trimethobenzamide. When this failed to control her symptoms, ondansetron was administered. Over the next 48 hours, she received three additional doses of ondansetron which effectively controlled her nausea and vomiting. The remainder of her postoperative course was uncomplicated.
Patient 4
An eight-year-old girl with a dilated cardiomyopathy was admitted to the ICU for inotropic support. She had suffered from viral myocarditis two years earlier and this had resulted in chronic congestive heart failure. She had been treated as an outpatient with oral medications, but had required several hospital admissions. Her cardiac function had deteriorated significantly and she was admitted on this occasion for inotropic support and evaluation for cardiac transplantation. Prior to and during her hospitalisation, she had persistent nausea and vomiting which was not controlled with oral promethazine. The serum digoxin level was 0.9 mcg/ml and the vomiting was thought to be the result of the low cardiac output state. Persistent vomiting precluded the administration of oral medications including potassium chloride, captopril, and digoxin. Ondansetron (0.15 mglkg/dose every 6 hours as needed) was administered intravenously and resulted in effective control of her symptoms. Although she had occasional bouts of nausea, no further vomiting occurred. Over the ensuing week, progressive cardiovascular instability developed and she subsequently expired.
Patient 5
A four-year-old boy was admitted to the ICU for treatment of pneumococcal meningitis. He had Anaesthesia and Intensil'e Care, Vol. 20, No. 4, November, 1992 sustained closed head trauma at the age oftwo, with a subsequent seizure disorder controlled with carbamazepine. Previous trials of other anticonvulsants, including phenytoin and phenobarbital, had been ineffective. Following admission to the ICU, the child developed episodic vomiting despite being given no oral intake and receiving intravenous hydration. The neurological examination was unremarkable. The child vomited his morning dose of carbamazepine on two separate occasions, one hour apart. Ondansetron was administered and 60 minutes later the dose of carbamazepine was repeated. No further vomiting occurred. The remainder of the hospital course was unremarkable.
DISCUSSION
Ondansetron is a selective inhibitor of central and peripheral serotonin receptors that has recently been used to control vomiting associated with chemotherapy,' radiation therapy2 and during the postoperative period. 3 To date, the majority of experience with its use has been in the control and prevention of chemotherapy induced emesis. This phenomenon is associated with increased plasma and urinary serotonin concentrations. Serotonin stimulates peripheral (vagal afferents) and central (chemoreceptor trigger zone) serotonin receptors leading to nausea and vomiting. The antiemetic properties of ondansetron are thought to result from central and peripheral serotonin receptor antagonism.
Although its use has not been previously reported in paediatric ICU patients, we have found ondansetron to be particularly effective in controlling vomiting without the adverse effects seen with other commonly administered antiemetics. Unlike other anti emetics (phenothiazines, metoclopramide), which are dopamine antagonists, ondansetron does not cause alterations in mental status or extrapyramidal effects. Sedation is also a common side-effect of the antihistamines (hydroxyzine) and anticholinergics (hyoscine). Although sedation may be beneficial in healthy patients during the postoperative period, alterations in mental status are unwanted and may be deleterious in the ICU patient in whom constant monitoring of the level of consciousness is mandatory. This was the case in three of our patients. The ongoing assessment of neurologic status is mandatory in patients with CNS infections such as meningitis, following craniotomy and in patients with potentially toxic ingestion. In such patients, we have found ondansetron to be the drug of choice to control nausea and vomiting, since it is not associated with sedation and other CNS effects (extrapyramidal movements).
In addition to generalised sedation, phenothiazines and antihistamines are known to potentiate the effects of narcotics. Although frequently administered with narcotics, to decrease the total narcotic requirement, these agents may also potentiate the respiratory depressant actions of narcotics. This occurred in our second patient. 4 When such effects may be deleterious, ondansetron can be expected to be an effective anti emetic without potentiation of narcotic-induced respiratory depression. Although controlled studies are needed to fully evaluate the applicability of ondansetron in such situations, we speculate that ondansetron might be efficacious particularly in patients with nausea and vomiting related to narcotic administration. This may be especially pertinent following spinal administration, since such patients may be at increased risk of delayed respiratory depression. Aside from sedation and alterations in mental status, adverse cardiovascular effects may occur with antiemetics. Antihistamines and anticholinergics may cause tachycardia. Although seldom deleterious in the paediatric population, these effects may be unwanted in adult patients due to increases in myocardial oxygen consumption. Phenothiazines also possess alpha-adrenergic blocking effects. In patients with a fixed stroke volume, alterations in systemic vascular resistance may lead to cardiovascular instability. These concerns led us to select ondansetron in our patient with a dilated cardiomyopathy.
In addition to interfering with enteral nutrition, nausea and vomiting may also restrict the oral administration of medications. This was the case in three of our patients. Ondansetron allowed the successful oral administration of several different medications including anticonvulsants (carbamazepine), cardiac medications including digoxin, potassium chloride and n-acetylcysteine (NAC). Although NAC is available for intravenous administration, this preparation is available in the United States only as an investigational agent and carries the risk of allergic reaction and, rarely, anaph ylaxis. 5 Although effective treatment of nausea and vomiting may significantly impact on the quality of life, vomiting may be the first sign of significant underlying pathology such as alterations in cardiac output or increased intracranial pressure. Therefore, a thorough evaluation and investigation into its aetiology is warranted, especially in the ICU patient.
We have found ondansetron to be an effective alternative to the more commonly administered antiemetics. Adverse effects described with its use have been limited and include lightheadedness, headache, and diarrhoea. 6 The only other disadvantage of ondansetron is its cost. In the United States, a dose for a 70 kg patient costs about $42, compared with $1 for promethazine and $6 for chlorpromazine. Comparable prices in Australia include $32 for ondansetron and $0.28 for metoclopramide. Because of these cost differences, ondansetron should be considered only when specific contraindications exist or adverse effects occur with more conventional antiemetics.
